Regenxbio's Duchenne gene therapy shows improved muscle function in trial
11/03/2026 15:59
March 11 (Reuters) - Regenxbio RGNX.O said on Wednesday that an interim data from a early-to-mid stage study of its experimental gene therapy in patients with Duchenne muscular dystrophy showed continued improvement in muscle function and a clean safety profile. (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics